Hair Depigmentation During Chemotherapy With a Class III/V Receptor Tyrosine Kinase Inhibitor
Shannon Routhouska, MD;
Anita C. Gilliam, MD, PhD;
Paradi Mirmirani, MD
Arch Dermatol. 2006;142:1477-1479.
Background Hair pigmentation is regulated by several factors including the interaction of the ligand stem cell factor (SCF) with its class III receptor tyrosine kinase, c-kit. An interruption of SCF/c-kit signal transduction results in hair depigmentation.
Observations A 69-year-old white woman developed hair depigmentation and fine-textured hair while being treated with the phase I chemotherapeutic agent GW786034, a class III/V receptor tyrosine kinase inhibitor. Discontinuation of therapy resulted in a reversal of these hair changes.
Conclusions Treatment with oral GW786034 resulted in reversible hair depigmentation and change in hair growth rate and texture, which were most likely due to an incomplete inhibition of SCF/c-kit signaling, although the exact mechanism is unknown. It would be intriguing to investigate topical tyrosine kinase inhibitors as a treatment for unwanted body hair.
Author Affiliations: Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pazopanib: An Oral Multitargeted Tyrosine Kinase Inhibitor for Use in Renal Cell Carcinoma
LaPlant and Louzon
The Annals of Pharmacotherapy 2010;44:1054-1060.
ABSTRACT
| FULL TEXT
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)
Prince et al.
Blood 2009;113:4819-4820.
FULL TEXT
Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles
Randall et al.
J Endocrinol 2008;197:11-23.
ABSTRACT
| FULL TEXT
|
